IRIDEX (NASDAQ:IRIX) Releases Earnings Results

IRIDEX (NASDAQ:IRIX) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($0.05) EPS for the quarter, Zacks reports. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

IRIDEX Price Performance

IRIX stock traded down $0.02 during midday trading on Thursday, reaching $0.88. 104,646 shares of the company’s stock traded hands, compared to its average volume of 39,815. The company has a 50-day simple moving average of $1.41 and a two-hundred day simple moving average of $1.60. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. IRIDEX has a 1-year low of $0.78 and a 1-year high of $3.65. The company has a market cap of $14.69 million, a price-to-earnings ratio of -1.32 and a beta of 0.94.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of IRIDEX in a report on Tuesday. They issued a “hold” rating on the stock.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.